The Apothecary Shops to distribute new Pfizer cancer drug

Specialty provider joins distribution network for Inlyta

PHOENIX — Specialty pharmacy provider The Apothecary Shops has inked a deal with Pfizer to distribute a new drug for treating kidney cancer.

The specialty provider announced Wednesday that Pfizer had granted it distribution rights for Inlyta (axitinib), which the Food and Drug Administration approved on Jan. 27 for advanced renal cell carcinoma in patients who have failed one systemic therapy.

"The Apothecary Shops is excited to be included in the limited network of pharmacies managing Inlyta," The Apothecary Shops president Keith Cook said. "We have a first-class oncology team, and this announcement certainly reinforces our strong position in the oncology market."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.